M4MM

TerrAscend Reports Q4 and FY 2025 Financial Results

TORONTO – In an industry still wrestling with persistent pricing compression, TerrAscend Corp. managed to hold the line on profitability while posting modest sequential growth in its latest quarter. The company released its financial results, ...

MariMed Reports Q4 and FY 2025 Financial Results

NORWOOD – MariMed Inc. released its fourth-quarter and full-year 2025 financial results, reporting a modest revenue increase that reflects the company’s focus on branded wholesale gains in an environment of sustained margin compression across multiple ...

New Jersey Clears Path for $6M Psilocybin Pilot

TRENTON – The New Jersey Legislature gave final approval last week to a measure that sets up a state-backed pilot program for psilocybin therapy, allocating $6 million to explore the compound's role in treating mental ...

TerrAscend Reports Q4 and FY 2025 Financial Results

TORONTO – In an industry still wrestling with persistent pricing compression, TerrAscend Corp. managed to hold the line on profitability while posting modest sequential growth in its latest quarter. The company released its financial results, ...

MariMed Reports Q4 and FY 2025 Financial Results

NORWOOD – MariMed Inc. released its fourth-quarter and full-year 2025 financial results, reporting a modest revenue increase that reflects the company’s focus on branded wholesale gains in an environment of sustained margin compression across multiple ...

Ohio to Award Dual-Use Cannabis Licenses by June

LOS ANGELES- Ohio is set to begin the transition to allow existing medical cannabis dispensaries to sell cannabis recreationally. The state's Joint Committee on Agency Rule Review has approved regulations for dual-use licenses, with applications ...

A Delays Hearing on Psychedelic Compounds

LOS ANGELES- The Drug Enforcement Administration (DEA) has postponed a crucial administrative hearing originally scheduled for June on the proposed ban of two psychedelic compounds, 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC). This decision follows a legal ...

Subscribe To Our Newsletter